title: Lack of prognostic value of human epidermal growth factor-like receptor 2 status in inflammatory breast cancer (IBC): a meta-analysis.
abstract: Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer which is more likely to be her-2/ neu amplified. While the her-2/neu status has been utilised to predict prognosis, the published data are inconsistent. The present meta-analysis was conducted to determine whether the her-2/neu status predicts outcomes. Papers were selected from the PubMed database based on defined inclusion and exclusion criteria. Parameters such as total patients, follow-up time and outcome statistics (i.e. overall survival (OS), relapse-free survival (RFS) were collected. The analysis included 6 studies with 2,838 IBC patients. The summary hazards ratio (HR) estimating the association of OS with HER-2-positive disease was 0.96 (95% confidence interval (95%CI: 0.85-1.10)), with similar findings for RFS (HR=0.81, 95%CI: 0.61-1.09). No obvious statistical heterogeneity was detected. This meta-analysis suggests that HER-2-positive status is not an independent adverse prognostic factor for survival among IBC patient cases.
authors.affiliation: Department of General Surgery, Jiangsu Cancer Hospital, The Affiliated Hospital of Nanjing Medical University, Nanjing, China E-mail : renzhaojun18@126.com, 673008034@qq.com.
authors.forename: Xiu-Juan
authors.initials: XJ
authors.lastname: Li
authors.forename: Quan-Bin
authors.initials: QB
authors.lastname: Zha
authors.forename: Xin-Yu
authors.initials: XY
authors.lastname: Xu
authors.forename: Lei
authors.initials: L
authors.lastname: Xia
authors.forename: Zhe
authors.initials: Z
authors.lastname: Zhang
authors.forename: Zhao-Jun
authors.initials: ZJ
authors.lastname: Ren
authors.forename: Jin-Hai
authors.initials: JH
authors.lastname: Tang
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000401:mortality*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000235:genetics; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism*; D015996:Survival Rate; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab